Form 4: Pfizer CEO Albert Bourla Reports Intra-Plan Transfer of Stock Units
SEC Form 4 Filing
Pfizer's CEO, Albert Bourla, reports an intra-plan transfer involving Pfizer stock units within the company's Supplemental Savings Plan.
Summary
- On March 4, 2024, Albert Bourla, the Chairman and CEO of Pfizer Inc., reported an intra-plan transfer.
- The transaction involved the acquisition of 88,240 Pfizer stock units in the Pfizer stock unit fund under the Pfizer Inc. Supplemental Savings Plan.
- These units were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
- The price per unit was $25.89.
- Following the reported transaction, Bourla directly owns 659,573 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reflecting standard executive compensation practices. There is no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common among publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and stock ownership.
- The filing ensures compliance with SEC regulations.
Key Dates
| Date | Description |
|---|---|
| 03/04/2024 | Date of the intra-plan transfer of Pfizer stock units. |
| 03/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.